TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06333990
Drug: Quetiapine Fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia, bipolar disorder, and as an adjunct to treat major depression. It has a broad spectrum of actions at dopaminergic (D1, D2, D3 and D4), serotonergic (5-HT2A, 5-HT2C and 5-HT7), adrenergic (α1), histaminic (H1) and muscarinic (mACh), and partial agonist at 5-HT1A receptors.
Study: NCT06333990
Drug: TAU
Normalized name: Tauvid
DrugBank: Flortaucipir F-18 (DB14914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care psychotropic medications for treatment of patients with mTBI.
Study: NCT04556721
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
Study: NCT06144255
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enrolled Participants for this trial will come for 3 study visits. The doses will be administered in varying order: participants will be randomized to one six possible permutations of the intranasal study doses (0, 500, 1000 U) of intranasal insulin at each visit.~Participants will undergo a fMRI scan before and after receiving intranasal doses. Additionally, participants will have blood samples taken.
Study: NCT05420285
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
Study: NCT06378268
Drug: Dydrogesterone 10 mg
Normalized name: dydrogesterone 10 MG
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone 10mg orally 2 times daily, starting on the day of gonadotropin injection to the oocyte maturation trigger night.
Study: NCT06378268
Drug: Cetrorelix 0.25 mg
Normalized name: cetrorelix 0.25 MG
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix 0.25mg is injected subcutaneously once a day. It is given from day 5 or day 6 of stimulation by the oocyte maturation trigger day.
Study: NCT04713891
Drug: KF-0210 tablets, 120 mg
DrugBank: KF-0210 (DB17476)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KF-0210 tablet will be orally administered as a single agent at 120 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
Study: NCT04713891
Drug: KF-0210 tablets, 240 mg
DrugBank: KF-0210 (DB17476)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KF-0210 tablet will be orally administered as a single agent at 240 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
Study: NCT04713891
Drug: KF-0210 tablets, 450 mg
DrugBank: KF-0210 (DB17476)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KF-0210 tablet will be orally administered as a single agent at 450 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
Study: NCT04713891
Drug: KF-0210 tablets, 600 mg
DrugBank: KF-0210 (DB17476)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KF-0210 tablet will be orally administered as a single agent at 600 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
Study: NCT04713891
Drug: KF-0210 (dosage RP2D-2) + Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: KF-0210 tablet will be orally administered at dosage RP2D-2 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
Study: NCT04713891
Drug: KF-0210 (dosage RP2D-1) + Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: KF-0210 tablet will be orally administered at dosage RP2D-1 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
Study: NCT04713891
Drug: KF-0210 (dosage RP2D) + Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: KF-0210 tablet will be orally administered at dosage RP2D once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
Study: NCT06392074
Drug: MB04
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05090280
Drug: Naltrexone Hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.
Study: NCT05090280
Drug: Nafamostat Mesylate
Normalized name: mesylate
DrugBank: Nafamostat (DB12598)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Maximum dose of 10 mg nafamostat co-administered with PF614 solution. Nafamostat will be dosed as an immediate-release (IR) solution or as prototype extended-release (ER) capsules.
Study: NCT00348023
Drug: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05983263
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin 8% patch (QUTENZA) apposed in coccygeal area
Study: NCT05004571
Drug: EQU-001
Normalized name: Eque-cel
DrugBank: Equecabtagene autoleucel (DB19016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQU-001 in 10 and 20 mg capsules
Study: NCT00000201
Drug: Selegiline
Normalized name: Selegiline
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03149211
Drug: UB-421
Normalized name: UB-612
DrugBank: UB-612 (DB16444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).
Study: NCT00000747
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04880109
Drug: APX-115
Normalized name: Apx-115 free base
DrugBank: Isuzinaxib (DB19109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of APX-115 100 mg capsule once daily for 14 days
Study: NCT05772273
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
Study: NCT05772273
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg Q2W for sib-matched donor HSCT patients, 100mg Q2W for haploidentical or unrelated donor HSCT patients.
Study: NCT06049693
Drug: Ferrous Gluconate 300 MG
Normalized name: ferrous gluconate 300 MG
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous Gluconate 300 MG twice a day
Study: NCT06431477
Drug: telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06431477
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06610305
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg twice daily (200 mg/day total) administered via oral capsule
Study: NCT06728371
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2mg/kg intravenous methadone given at induction
Study: NCT06728371
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2mg/kg intravenous morphine given at induction
Study: NCT05256446
Drug: AMG 701
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03630081
Drug: WCK 4282 (FEP-TAZ) 4 g
Normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WCK 4282 (FEP-TAZ) 4 g \[2 g FEP and 2 g TAZ\] IV q8h, infused over 90 min
Study: NCT03630081
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 g IV q8h, infused over 45 min
Study: NCT03630081
Drug: ciprofloxacin 500 mg Optional Oral Switch
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ciprofloxacin 500 mg PO q12h
Study: NCT05528887
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-5 to D-3: Fludarabine (30 mg/m\^2/day) will be administered intravenously for 3 days.
Study: NCT05350085
Drug: Remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ① initial dose: use a micro injection pump to pump remimazolam at the rate of 50mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation ; ② Maintenance dose: maintain the pump speed at 5 \~ 10mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
Study: NCT05350085
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ① initial dose: use a micro injection pump to pump remazolam at the rate of 30mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation; ② Maintenance dose: maintain the pump speed at 3 \~ 6mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
Study: NCT05107219
Drug: Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05107219
Drug: Plecanatide
Normalized name: Plecanatide
DrugBank: Plecanatide (DB13170)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04463615
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05911217
Drug: CT041 autologous CAR T-cell injection
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: CT041 (DB18288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion
Study: NCT04686643
Drug: AGLS
Normalized name: Aglucosidase alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: S-amlodipine, Valsartan
Study: NCT05288153
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be instructed to take one tablet(500mg) of metformin after breakfast every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
Study: NCT05288153
Drug: Folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be instructed to take one tablet(5mg) of folate three times every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
Study: NCT03629327
Drug: ASA 81mg
Normalized name: ASA 81MG/PRAVASTATIN NA 20MG TAB
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months
Study: NCT00000736
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03629327
Drug: ASA 325mg
Normalized name: AL OH/ASA 325MG/MG OH TAB
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months
Study: NCT06425978
Drug: Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blissel®, Estriol vaginal gel 50 micrograms/g, daily application for 15-21 days in a row, then two times a week for 24 weeks (6 months). Application instructions will be explained to the patients. The gel should be applied in the vagina using an applicator with the marked dose, the full applicator should be inserted into the vagina and emptied, preferably at night.
Study: NCT05039099
Drug: AP-101
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive AP-101 by intravenous infusion (IV).
Study: NCT05988372
Drug: Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
Study: NCT05988372
Drug: Albumin-paclitaxel + Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
Study: NCT05909852
Drug: ABP 501-HCF
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single-dose SC injection of ABP 501-HCF.
Study: NCT05909852
Drug: ABP 501-LCF
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single-dose SC injection of ABP 501-LCF
Study: NCT05201118
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor, 20 mg/tablet, is a first-in-class, oral Selective-Inhibitor-of-Nuclear-Export (SINE) compound that impedes XPO-1which is a major nuclear export protein of macromolecular cargo frequently overexpressed in MM.
Study: NCT05201118
Drug: CT103A
Normalized name: CT103A
DrugBank: CT103A (DB18180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
Study: NCT06140420
Drug: Naltrexone Oral Product
Normalized name: naltrexone Oral Product
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic, oral tablet.
Study: NCT02473497
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
Study: NCT06243692
Drug: Lacosamide 50 MG
Normalized name: lacosamide 50 MG
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT06243692
Drug: Topiramate 50Mg Tab
Normalized name: TOPIRAMATE 50MG TAB
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT05750758
Drug: rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rivaroxaban 2.5mg bid for 1m
Study: NCT06414707
Drug: Vonoprazan, Amoxicillin and Levofloxacin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group (1) included 160 patients received Vonoprazan 20 mg oral once daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
Study: NCT06414707
Drug: Pantoprazole 40mg, Amoxicillin and Levofloxacin
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group (2) included 160 patients received Pantoprazole 40 mg oral twice daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
Study: NCT04696380
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will sample high vs low nicotine.
Study: NCT05689359
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine will be administered at 600 mg po BID for 3 days prior to starting chemotherapy, continued during the course of chemotherapy, and for 7 days after chemotherapy.
Study: NCT02556411
Drug: LNG-IUS 13,5 mg Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LNG-IUS
Study: NCT05378048
Drug: PDO-guided treatment
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO.
Study: NCT06353360
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab will be given 300 mg intravenously every 4 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. The Tislelizumab treatment should be continued until confirmed PD, unacceptable toxicity, or finished Tislelizumab treatment for other reasons.
Study: NCT06353360
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will carry out 6 cycles of TMZ adjuvant chemotherapy according to the instructions. The dosage of TMZ is 150-200 mg/(m2·d), daily for 5 days followed by 23 days without treatment, the treatment cycle is 28 days. The initial dose of cycle 1 is 150 mg/(m2·d), if patients do not experience TMZ chemotherapy toxicity, the dose should be increased to 200 mg/(m2·d) in subsequent treatment cycles. After 6 cycles of TMZ adjuvant chemotherapy, if the patients do not experience disease progression, it is recommended to continue TMZ adjuvant chemotherapy, or treated according to investigators' recommendations. The TMZ treatment should be continued until confirmed progressive disease (PD), unacceptable toxicity, or finished TMZ treatment for other reasons.
Study: NCT06414473
Drug: Cannabidiol (CBD) Extract
Normalized name: cannabidiol (CBD) extract
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered thrice daily (with food) using a sublingual route of administration
Study: NCT05438706
Drug: chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide, an HDAC inhibitor
Study: NCT05438706
Drug: camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
Study: NCT05438706
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin \[diammine(1,1-cyclobutanedicarboxylato)platinum(II)\] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
Study: NCT06211881
Drug: Chi-GVM
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle.
Study: NCT00000731
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05229874
Drug: carbon nanoparticles
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic injection
Study: NCT05229874
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Endoscopic injection
Study: NCT05110768
Drug: Triferic AVNU
Normalized name: FERRIC PYROPHOSPHATE CITRATE 1.5 mg in 1 mL INTRAVENOUS SOLUTION [Triferic AVNU]
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triferic AVNU is an iron salt that is approved for the maintenance of Hgb in chronic kidney disease patients on hemodialysis. It is experimental in this study because it has not yet been approved for patients receiving home infusion therapy